Exemestane
Showing 26 - 50 of 366
Metastatic Breast Cancer Trial in Johannesburg (Palbociclib, Exemestane, Goserelin)
Recruiting
- Metastatic Breast Cancer
- Palbociclib
- +2 more
-
Johannesburg, South AfricaWits Oncology center
Jul 22, 2021
Breast Cancer Trial in Shanghai (OFS + Anastrozole, OFS + Exemestane)
Completed
- Breast Cancer
- OFS + Anastrozole
- OFS + Exemestane
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiaotong University School of Medicine
Mar 28, 2022
Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)
Active, not recruiting
- Breast Cancer
- Capecitabine
- Aromatase Inhibitor
-
Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen Uni
Jan 27, 2023
Early-stage Breast Cancer Trial in Ottawa (Endocrine Therapy and Radiotherapy)
Completed
- Early-stage Breast Cancer
- Endocrine Therapy and Radiotherapy
-
Ottawa, Ontario, CanadaOttawa Hospital Research Institute
Sep 28, 2022
Breast Tumors Trial in Mönchengladbach (drug, diagnostic test, procedure)
Active, not recruiting
- Breast Neoplasms
- Perjeta Injectable Product
- +13 more
-
Mönchengladbach, GermanyEvangelisches Krankenhaus Bethesda Mönchengladbach
Oct 4, 2022
Breast Cancer, Early Breast Cancer Trial (Camizestrant, Tamoxifen, Anastrozole)
Not yet recruiting
- Breast Cancer, Early Breast Cancer
- Camizestrant
- +5 more
- (no location specified)
Jul 11, 2023
Premenopausal Breast Cancer Trial in Taipei (Pembrolizumab/ Exemestane/ Leuprolide)
Recruiting
- Premenopausal Breast Cancer
- Pembrolizumab/ Exemestane/ Leuprolide
-
Taipei, TaiwanNational Taiwan University Hospital
May 6, 2021
Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma Trial in United States (Abemaciclib, Tamoxifen,
Not yet recruiting
- Breast Cancer
- +2 more
- Abemaciclib
- +5 more
-
Boston, Massachusetts
- +7 more
Aug 14, 2023
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer Trial (palbociclib and exemestane plus trastuzumab and
Not yet recruiting
- Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
- palbociclib and exemestane plus trastuzumab and pyrotinib
- (no location specified)
Apr 23, 2021
Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer Trial (Ribociclib, Fulvestrant,
Not yet recruiting
- Locoregional Recurrence
- +2 more
- Ribociclib
- +4 more
- (no location specified)
Jul 18, 2022
Metastatic Breast Cancer Trial in Springfield, Rochester, Lebanon (17B-estradiol, Letrozole, Anastrozole)
Active, not recruiting
- Metastatic Breast Cancer
- 17B-estradiol
- +3 more
-
Springfield, Massachusetts
- +2 more
Nov 1, 2022
Metastatic Breast Cancer Trial in United States (Sabizabulin, Exemestane monotherapy, exemestane plus everolimus, or selective
Not yet recruiting
- Metastatic Breast Cancer
- Sabizabulin
- Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
-
Anchorage, Alaska
- +25 more
Dec 22, 2022
Metastatic Breast Cancer Trial in Chuo-ku, Nihonbashi, Koami-cho (Paclitaxel, Bevacizumab, Letrozole)
Completed
- Metastatic Breast Cancer
- Paclitaxel
- +7 more
-
Chuo-ku, Nihonbashi, Koami-cho, Tokyo, JapanJapan Breast Cancer Research Group
Aug 2, 2022
Metastatic Breast Cancer Trial in United States (Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane
Recruiting
- Metastatic Breast Cancer
- Enobosarm & Abemaciclib Combo
- non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
-
Chandler, Arizona
- +29 more
Feb 1, 2023
Breast Cancer, Quality of Life Trial in Chapel Hill (Accelerated Partial Breast Irradiation (APBI), tamoxifen, anastrozole,
Recruiting
- Breast Cancer
- Quality of Life
- Accelerated Partial Breast Irradiation (APBI)
- tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
-
Chapel Hill, North CarolinaUniversity of North Carolina
Jul 22, 2022
Breast Cancer, Hormone Receptor Positive Tumor Trial in Tampa (Durvalumab, Anastrozole 1mg, Letrozole 2.5mg)
Terminated
- Breast Cancer
- Hormone Receptor Positive Tumor
- Durvalumab
- +3 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
May 27, 2022
Breast Cancer Female Trial in Charlottesville, Richmond (tamoxifen, letrozole, anastrozole, or exemestane, Patient reported
Recruiting
- Breast Cancer Female
- tamoxifen, letrozole, anastrozole, or exemestane
- Patient reported outcomes
-
Charlottesville, Virginia
- +1 more
Mar 16, 2022
Metastatic Breast Cancer Trial in Guangzhou, Shantou (Mecapegfilgrastim, dalpiciclib, exemestane, fulvestrant, letrozole,
Not yet recruiting
- Metastatic Breast Cancer
- Mecapegfilgrastim
- +2 more
-
Guangzhou, Guangdong, China
- +2 more
Jul 17, 2022
Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor Trial in Stockholm (Paclitaxel, Tamoxifen + Palbociclib,
Active, not recruiting
- Early-Stage Breast Carcinoma
- Estrogen Receptor Positive Tumor
- Paclitaxel
- +3 more
-
Stockholm, Sweden
- +2 more
Jul 30, 2021
Breast Cancer Trial in Baltimore (Tamoxifen Citrate, Letrozole, Exemestane)
Recruiting
- Breast Cancer
- Tamoxifen Citrate
- +4 more
-
Baltimore, MarylandJohns Hopkins Bayview Hospital
Nov 30, 2021
Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer Trial in Lexington (Anastrozole 1mg, Letrozole 2.5mg,
Recruiting
- Breast Cancer
- +3 more
- Anastrozole 1mg
- +3 more
-
Lexington, KentuckyUniversity of Kentucky Markey Cancer Center
Jan 3, 2022